Cancer Epidemiology

$78,039P30FY2014CANIH

Dana-Farber Cancer Inst, Boston MA

Investigators

Linked publications, trials & patents

Paper 39713466 Paper 39666914 Paper 39605676 Paper 39593217 Paper 39536083 Paper 39532885 Paper 39484503 Paper 39389170 Paper 39322760 Paper 39168126 Paper 39160372 Paper 39107288 Paper 39042477 Paper 39025073 Paper 39024561 Paper 38996877 Paper 38992034 Paper 38979326 Paper 38979245 Paper 38942046 Paper 38924531 Paper 38889153 Paper 38861327 Paper 38815709 Trial NCT03029325 Trial NCT02627430 Trial NCT02142803 Trial NCT02097225 Trial NCT02079740 Trial NCT01940809 Trial NCT01835184 Trial NCT01822509 Trial NCT01575522 Trial NCT01434316 Trial NCT01307631 Trial NCT01283035 Trial NCT01116648 Trial NCT01026324 Trial NCT00956163 Trial NCT00888134 Trial NCT00662506 Trial NCT00622401 Trial NCT00458978 Trial NCT00458549 Trial NCT00429910 Trial NCT00400946 Trial NCT00376480 Trial NCT00357500 Trial NCT00301093 Trial NCT00126672 Trial NCT00101075 Trial NCT00098865 Trial NCT00098514 Trial NCT00096291 Trial NCT00095927 Trial NCT00095901 Trial NCT00095875 Trial NCT00095836 Trial NCT00090857 Trial NCT00084838 Trial NCT00083031 Trial NCT00079326 Trial NCT00072436 Trial NCT00069940 Trial NCT00053976 Trial NCT00052611 Trial NCT00047294 Trial NCT00047281 Trial NCT00020670 Trial NCT00020605 Trial NCT00007917 Trial NCT00006107 Trial NCT00005988 Trial NCT00005096 Trial NCT00004180 Trial NCT00004163 Trial NCT00004070 Trial NCT00003761 Trial NCT00003744 Trial NCT00003657 Trial NCT00003200 Trial NCT00003058 Trial NCT00003045 Patent 9512485 Patent 7786269 Patent 7396678 Patent 7229755 Patent 7048929 Patent 6908617 Patent 6479284 Patent 6479281 Patent 5861424 Patent 5670530 Patent 5618831 Patent 5502214 Patent 5360803 Patent 4625014 Patent 4618492 Patent 4542225 Patent 4035566

Abstract

PROJECT SUMMARY (See instructions): The specific aims of the Cancer Epidemiology Program are to evaluate the following factors in relation to cancer risk and survival: 1. Hormonal markers and other intermediate markers (e.g., metabolomics) as well as energy balance. 2. Genetic and epigenetic markers, with an emphasis on their interaction with environmental factors. Chronic inflammatory processes, as assessed through lifestyle, molecular markers and use of anti-inflammatory drugs. 3. Diet, including vitamin D, folate and other nutritional contributors to one-carbon metabolism. The Program focuses on exposures over the life course, including childhood and adolescence. Further, exposures are evaluated in relation to specific molecular characteristics of the tumor, analyses that can greatly enhance the understanding of etiologic pathways and provide support for causality. Cancer Epidemiology has been a Program since the formation of DF/HCC. The Program is led by S. Hankinson BWH) and W. Willett(HSPH) and includes 59 members representing five of the Harvard member institutions and 11 departments across Harvard Medical School and Harvard School of Public Health. The Program was rated outstanding at its last review. Program members have $24.3 million in research funding (total costs), including $20.2 million in NCI funding and $3.7 million in other peer reviewed funding. Program members published 1,295 papers (2006 to 2010). Of these, ,30% were intra-programmatic, 43% of these were interprogrammatic collaborations and 35% were inter-institutional.

View original record on NIH RePORTER →